Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its weight loss drug program. It is guiding for margin expansion and fast ...

Fast growth, concerns over weight loss product Q4 2024 showed more blockbuster growth for Hims & Hers. Revenue growth ...

However, given how fast revenue is growing and its positive free cash flow, Hims & Hers seems to be getting a good return on this marketing spend. So what's the problem? Why is the stock down?

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...